LONDON (Alliance News) - Scancell Holdings PLC shares were up in early trade on Tuesday after the company said it has seen positive results for its SCIB1 trials on malignant melanoma treatment.
Scancell shares were up 10% to 33.32 pence in early trade on Tuesday, making it one of the best performers on the AIM All-Share.
The company, which develops immunotherapy treatments for cancer, said it has seen strong survival and safety data from the Phase 1 and 2 clinical trials conducted on SCIB1, its ImmunoBody platform vaccine.
The results showed the product has the potential to become the first effective standalone treatment for adjuvant melanoma, Scancell said. Adjuvant therapy is treatment provided in addition to the primary, main or initial treatment.
It said all 16 patients with fully resected disease are still alive, with a median survival time of 26 months after starting treatment. Only four of the patients in the trial showed disease progression.
Scancell said adjuvant melanoma represents a significant new market opportunity for the SCIB1 product.
Elsewhere, the company said its Modi-1 product from its Moditope platform is on schedule to start clinical trials in 2016 and said two new Moditope protein targets have been identified. Modi-1 is the first immunotherapeutic product from the Moditope platform.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)